Cardiovascular disease remains – despite the development of new drugs, devices, and therapeutic strategies – the leading cause of death and disability worldwide. There is therefore a great need to implement the pharmacological armamentarium, considering also the need to balance the therapeutic and the side effects. Furthermore, the best choice among the drug treatment options and reduction of side effects remain urgent problems for studies of cardiovascular disease. In this context, drug repurposing could be an innovative way and opportunity to extend and improve pharmacological tools. Indeed, applying well-established drugs and compounds to new indications, drug repurposing has already been proven efficient and safe in humans. Furthermore, this approach generates lower costs and needs shorter time for approval than the development of a de novo drug. In the current review, we discuss the main evidence for the repurposing in cardiovascular diseases of drugs approved and marketed for other pathologies by reviewing their mechanisms of action and the results reported in observational and then in randomized studies.
Drug repurposing in cardiovascular diseases : Opportunity or hopeless dream? / P. Gelosa, L. Castiglioni, M. Camera, L. Sironi. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 177(2020 Jul), pp. 113894.1-113894.15. [10.1016/j.bcp.2020.113894]
Drug repurposing in cardiovascular diseases : Opportunity or hopeless dream?
P. Gelosa;M. Camera;L. Sironi
2020
Abstract
Cardiovascular disease remains – despite the development of new drugs, devices, and therapeutic strategies – the leading cause of death and disability worldwide. There is therefore a great need to implement the pharmacological armamentarium, considering also the need to balance the therapeutic and the side effects. Furthermore, the best choice among the drug treatment options and reduction of side effects remain urgent problems for studies of cardiovascular disease. In this context, drug repurposing could be an innovative way and opportunity to extend and improve pharmacological tools. Indeed, applying well-established drugs and compounds to new indications, drug repurposing has already been proven efficient and safe in humans. Furthermore, this approach generates lower costs and needs shorter time for approval than the development of a de novo drug. In the current review, we discuss the main evidence for the repurposing in cardiovascular diseases of drugs approved and marketed for other pathologies by reviewing their mechanisms of action and the results reported in observational and then in randomized studies.File | Dimensione | Formato | |
---|---|---|---|
Gelosa P et al_Drug repurposing in cardiovascular diseases_clean version.pdf
Open Access dal 04/07/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
457.7 kB
Formato
Adobe PDF
|
457.7 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S0006295220301222-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.41 MB
Formato
Adobe PDF
|
2.41 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.